Welcome to Anagrammer Crossword Genius! Keep reading below to see if ranspi is an answer to any crossword puzzle or word game (Scrabble, Words With Friends etc). Scroll down to see all the info we have compiled on ranspi.
ranspi
Searching in Crosswords ...
The answer RANSPI has 0 possible clue(s) in existing crosswords.
Searching in Word Games ...
The word RANSPI is NOT valid in any word game. (Sorry, you cannot play RANSPI in Scrabble, Words With Friends etc)
There are 6 letters in RANSPI ( A1I1N1P3R1S1 )
To search all scrabble anagrams of RANSPI, to go: RANSPI?
Rearrange the letters in RANSPI and see some winning combinations
Scrabble results that can be created with an extra letter added to RANSPI
6 letters out of RANSPI
4 letters out of RANSPI
3 letters out of RANSPI
Searching in Dictionaries ...
Definitions of ranspi in various dictionaries:
No definitions found
Word Research / Anagrams and more ...
Keep reading for additional results and analysis below.
| Ranspi might refer to |
|---|
| Ranpirnase is a ribonuclease enzyme found in the oocytes of the Northern Leopard Frog (Rana pipiens). Ranpirnase is a member of the pancreatic ribonuclease (RNase A) protein superfamily and degrades RNA substrates with a sequence preference for uracil and guanine nucleotides. Along with amphinase, another leopard frog ribonuclease, ranpirnase has been studied as a potential cancer treatment due to its unusual mechanism of cytotoxicity tested against tumor cells.Ranpirnase was originally discovered by scientists at TamirBio, a biotechnology company (formerly Alfacell Corporation), where it was tested in preclinical assays and in clinical trials under the name Pannon or Onconase, respectively. The mechanism of action of ranpirnase tumor-selective cytotoxicity has been attributed to the RNA interference pathway, potentially through cleaving siRNA molecules; to cleavage of transfer RNA; and to interference with the NF-κB pathway. Despite early indications of promise as a mesothelioma treatment, and an orphan drug status designation from the United States Food and Drug Administration in 2007, the Phase III clinical trial for this indication did not demonstrate statistical significance against primary endpoints. Currently (as of May 2017) Ranpirnase is in Phase I clinical study for treatment of anogenital warts. |